Non-alcoholic fatty liver disease: Current therapeutic options.

Avik Majumdar, Jef Verbeek, Emmanuel A Tsochatzis

Journal: Current opinion in pharmacology 2021;61():98-105

PMID: 34688168

Full Text on Elsevier Science View on PubMed

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and has an estimated global prevalence of 25%. NAFLD is found in up to 80% of people with obesity and over 60% of patients with diabetes. Cardiovascular disease is the main cause of mortality, followed by extra-hepatic cancers and then liver-specific complications of cirrhosis and hepatocellular carcinoma. Lifestyle modification remains the primary intervention in NAFLD. Weight loss achieved through dietary modification and exercise can lead to histologic improvement and reversal of metabolic complications. Current drug therapy is limited to pioglitazone and vitamin E; however, several agents are currently under phase III development. This review summarises the current treatment options in NAFLD.

Address: AW Morrow Gastroenterology and Liver Centre, Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, Australia; Central Clinical School, The University of Sydney, Australia.; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Hepatology, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.; UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK; Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK. Electronic address: [email protected].

DOI: 10.1016/j.coph.2021.09.007

Link outs

Free resources

Medical:

https://medlineplus.gov/fattyliverdisease.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Exercise, Humans, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Obesity, Pioglitazone